Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial symbols : Bmy save search
Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn’s Disease
Published: 2024-03-28 (Crawled : 22:00) - biospace.com/
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: 0.26%
H: 2.03%
C: 1.57%
first disease active update trial
Bristol Myers Squibb Announces CheckMate -9DW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Meets Primary Endpoint of Overall Survival for the First-Line Treatment of Advanced Hepatocellular Carcinoma
Published: 2024-03-20 (Crawled : 12:00) - biospace.com/
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: -0.33%
H: 1.02%
C: 0.48%
opdivo treatment trial advanced plus
Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial
Published: 2024-02-22 (Crawled : 12:00) - globenewswire.com
IMCR | $54.765 0.34% 0.34% 430K
|
Manufacturing
|
| O: 0.91%
H: 0.95%
C: -2.05%
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: -0.65%
H: 1.63%
C: 1.48%
melanoma nivolumab collaboration trial advanced agreement
Abecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3
Published: 2023-12-12 (Crawled : 08:00) - biospace.com/
TSVT | $4.65 -8.1% -8.82% 710K
|
|
| O: -4.02%
H: 9.35%
C: 4.84%
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: -0.57%
H: 0.28%
C: -0.57%
therapy
Bristol Myers Squibb Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab)
Published: 2023-12-07 (Crawled : 18:00) - biospace.com/
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: 0.84%
H: 1.39%
C: -0.28%
opdivo trial plus
Karyopharm Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD™ Agent CC- 92480 Mezigdomide in Combination with Selinexor in Patients with Relapsed/Refractory Multiple Myeloma
Published: 2023-10-30 (Crawled : 13:00) - biospace.com/
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: 1.39%
H: 0.32%
C: -0.93%
KPTI | $1.265 -8.33% -9.09% 1.3M
|
Health Technology
|
| O: 2.92%
H: 6.08%
C: -3.35%
collaboration trial
Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023
Published: 2023-10-23 (Crawled : 11:00) - globenewswire.com
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: -0.19%
H: 0.66%
C: -0.62%
ADXS | $0.6455 12.48% 2.3K
|
Health Technology
|
| O: 0.0%
H: 5.56%
C: 0.0%
al102 congress tumors pharmaceuticals trial results phase 2
Phase 3 CheckMate -67T Trial of Subcutaneous Nivolumab (nivolumab and hyaluronidase) Meets Co-Primary Endpoints in Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Published: 2023-10-19 (Crawled : 12:00) - biospace.com/
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: -0.37%
H: 0.56%
C: -0.28%
nivolumab renal cell trial
Neoadjuvant Opdivo (nivolumab) with Chemotherapy Provides Benefits for Patients with Resectable Non-Small Cell Lung Cancer Across PD-L1 Expression Levels with Three-Year Follow Up in CheckMate -816 Trial
Published: 2023-10-17 (Crawled : 00:00) - biospace.com/
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: -0.03%
H: 0.87%
C: 0.38%
lung opdivo cancer cell trial benefits
Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Shows Significant Improvement in Event-Free Survival for Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -77T Trial
Published: 2023-10-17 (Crawled : 00:00) - biospace.com/
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: -0.03%
H: 0.87%
C: 0.38%
lung opdivo cancer cell trial
Paradigm and Bristol Myers Squibb collaborate to build a new model for clinical trials
Published: 2023-10-06 (Crawled : 12:00) - biospace.com/
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: -0.3%
H: 1.12%
C: 0.73%
trials
Six-Year Outcomes from Phase 3 CheckMate -227 Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer
Published: 2023-09-11 (Crawled : 14:00) - biospace.com/
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: -0.12%
H: 1.11%
C: 0.1%
lung opdivo cancer cell treatment trial plus show
Long-Term Follow-Up Data from Two Phase 3 Studies of CAMZYOS® (mavacamten) Demonstrate Consistent and Durable Response in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)
Published: 2023-08-28 (Crawled : 19:00) - biospace.com/
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: -0.03%
H: 0.56%
C: -0.68%
camzyos response
Updated Data from TRIDENT-1 Trial Show Durable Efficacy Benefits with Repotrectinib for Patients with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
Published: 2023-08-16 (Crawled : 18:00) - biospace.com/
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: -0.66%
H: 0.46%
C: -0.67%
lung cancer cell trial show benefits
Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy Shows Overall Survival and PFS Benefit for Cisplatin-Eligible Patients with Unresectable or Metastatic Urothelial Carcinoma in the Phase 3 CheckMate -901 Trial
Published: 2023-07-11 (Crawled : 12:00) - biospace.com/
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: -0.26%
H: 0.96%
C: 0.75%
opdivo trial
AVEO Oncology Announces Completion of Enrollment in Pivotal Phase 3 TiNivo-2 Study of FOTIVDA® (tivozanib) in Combination with OPDIVO® (nivolumab) in Advanced Renal Cell Carcinoma
Published: 2023-06-27 (Crawled : 22:00) - biospace.com/
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: -0.06%
H: 0.46%
C: 0.0%
fotivda renal cell study
U.S. Food and Drug Administration Approves Addition of Positive Data from Phase 3 VALOR-HCM Study to CAMZYOS® (mavacamten) Label
Published: 2023-06-16 (Crawled : 10:00) - biospace.com/
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: 0.32%
H: 2.1%
C: 1.97%
camzyos drug label food positive study
Bristol Myers Squibb’s Investigational LPA1 Antagonist Reduces the Rate of Lung Function Decline in Patients with Idiopathic Pulmonary Fibrosis
Published: 2023-05-22 (Crawled : 21:00) - biospace.com/
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: 0.0%
H: 0.7%
C: -0.05%
lung fibrosis
Neoadjuvant Opdivo (nivolumab) with Chemotherapy Demonstrates Long-Term, Durable Clinical Benefits for Patients with Resectable Non-Small Cell Lung Cancer at Three Years in the CheckMate -816 Trial
Published: 2023-03-30 (Crawled : 15:00) - biospace.com/
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: 0.29%
H: 0.22%
C: -0.26%
lung opdivo cancer cell trial benefits
BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1 Trial for SHP2 Inhibitor BBP-398 in Combination with Bristol Myers Squibb’s OPDIVO® (nivolumab)
Published: 2023-03-23 (Crawled : 13:00) - biospace.com/
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: 0.52%
H: 0.46%
C: -0.9%
BBIO | $24.98 0.0% 2M
|
Health Technology
|
| O: 0.62%
H: 5.65%
C: 5.11%
bbp-398 opdivo lung pharma cancer trial phase 1
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.